Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$39.75
▼ $17.60 (-30.7%)
Market data updated: 09/19 09:16 PM
Fundamentals updated: 09/19/2026
News analyzed: 09/19/2026
Market Cap
$3.85B
Day Range
$39.08 - $44.85
52-Week Range
$35.97 - $72.66
Beta
—
Next Earnings
02.11.2026
Support
$39.08
Resistance
$71.03
XENE is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+5.3% (1Y)
Strengths: 2/26 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🔴 Bearish
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Liquidity risk
Current ratio: 13.42
Risk
Biggest negative driver
DCF Fair Value
Estimated fair value: -$46.66 vs. price $39.75 (-217.4%)
Fair Value
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
29
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
today · $39.75
Evidence: Panic-selling score jumped from 19 to 80 day-over-day
What happened after
Still awaiting outcome
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
32
Quality
42
Value
38
Momentum
10
Risk
40
Sentiment
38
Fundamental
30
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Xenon Pharmaceuticals Inc. has centered on its **Phase 3 clinical progress for azetukalner**, a potential epilepsy treatment, with a focus on topline results from the **X-TOLE2 study** presented at the European Epilepsy Congress. The company also highlighted **long-term extension data** and mechanistic insights, suggesting azetukalner’s potential as an additive therapy alongside existing anti-seizure drugs. Additionally, Xenon announced participation in the **Wells Fargo Healthcare Conference** and recent **Nasdaq-compliant equity inducement grants** for new employees.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Xenon Pharmaceuticals Inc. - Common. News trend score: 38. Reason: 9 of the last 20 articles are negative, versus 7 positive.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
69
🎯 Conviction (vs. Emotion)
48
Psychology
83
Fundamentals
30
Technical
10
Valuation
38
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price (3M)
-25%
Market Narrative
28
Fundamental Reality
48
Narrative Gap
-20
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The dominant anchoring behavior (57) suggests traders are fixating on the 2.1% support level, possibly due to recent price action. Herding (47) hints at passive alignment with peers, but the stock’s underperformance today weakens this. Euphoria (19) is muted by technical signals despite extreme sentiment, implying skepticism. The key question: will traders break support or hold near the anchor? Narrative-reality gap (16) may reflect optimism over fundamentals.
Updated: 09/09/2026, 09:41 AM
What could change this?
👥 What the crowd believes
"topline Phase 3 X-TOLE2 results in focal onset seizures"
"mechanistic data suggesting azetukalner may offer additive benefits in combination with anti-seizure medications"
"six data presentations at the 16th European Epilepsy Congress"
🧠 Market Brain events driving this
📈 9D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Charles Mackay — 100/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
Based on Bagehot's documented liquidity criteria, the model estimates XENE would likely survive a credit squeeze, while Nelson’s cycle‑position rules also give it a high score, reflecting an oversold stance. In contrast, Graham’s defensive and enterprising screens, which stress statistical cheapness and strong balance‑sheet safety, rate the stock poorly, and Livermore’s trend‑following rule flags a negative trend. Marks and Loeb sit in the middle, seeing reasonable risk but no compelling cycle‑timing edge, whereas Schwager and the efficient‑market view find no clear advantage. Veblen, Housel, Lynch, and Fisher assign the lowest scores because the stock appears volatile, growth‑driven without quality, and fails their growth‑at‑reasonable‑price or long‑term stability standards.
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 100
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 100
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 100
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟢 72
Risk appears reasonably priced — no obvious cycle-timing red flag
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 70
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 44
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 43
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 39
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 25
Doesn't show the stability Smith's long-term case requires
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 21
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 19
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 18
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 11
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 40%
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 9
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (0 bullish · 10 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
-4974.3%
Net Margin
-4612.1%
EBITDA Margin
-4940.4%
ROE
-59.5%
ROA
-54.6%
ROIC
—
EPS
-$4.36
Cash
$199.16M
Total Debt
—
Current Ratio
13.42
Debt/Equity
—
How is Fair Value calculated? →
Current Price
$39.75
Estimated Fair Value (DCF)
-$46.66
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-217.4%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
-5.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | -5.0% | $-265.92M | $-243.96M |
| 2 | -3.1% | $-257.61M | $-216.83M |
| 3 | -1.2% | $-254.39M | $-196.44M |
| 4 | 0.6% | $-255.98M | $-181.34M |
| 5 | 2.5% | $-262.38M | $-170.53M |
Base FCF (last actual year)
$-279.92M
Terminal Value
$-4.14B
Present Value of Terminal Value
$-2.69B
Enterprise Value
$-3.70B
Net Debt
$0
Equity Value
$-3.70B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$7.34
Tangible Book Value per Share (Tangible NAV)
$7.34
Sentiment based on basic keywords (not AI) — 7 positive, 4 neutral, 9 negative out of the last 20 articles.
Yahoo · 18.9.2026
Yahoo · 18.9.2026
ChartMill · 18.9.2026
Yahoo · 18.9.2026
Yahoo · 18.9.2026
ChartMill · 18.9.2026
Yahoo · 18.9.2026
Yahoo · 18.9.2026
Yahoo · 18.9.2026
Yahoo · 18.9.2026
ChartMill · 18.9.2026
Yahoo · 18.9.2026
Benzinga · 18.9.2026
ChartMill · 18.9.2026
SeekingAlpha · 18.9.2026
Benzinga · 18.9.2026
Yahoo · 18.9.2026
Yahoo · 18.9.2026
Yahoo · 18.9.2026
Benzinga · 18.9.2026
Xenon Pharmaceuticals Inc. - Common (XENE) currently has a StockIQ AI score of 29/100, rated "Weak". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
XENE currently scores 29/100 (Weak) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, XENE's estimated fair value is -$46.66, which is 217.4% below the current price of $39.75. This is one valuation model among several signals in the fair-value category, not a price target.
XENE's technical score is 10/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Current ratio: 13.42; Current ratio: 13.42.
Based on the real signals StockIQ computed: Estimated fair value: -$46.66 vs. price $39.75 (-217.4%); Operating margin: -4974.3% (negative); Net margin: -4612.1% (negative).
StockIQ has no recorded dividend payment history for XENE.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 10 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Svoronos Dawn | Exercise of Derivative Securities | 1.9.2026 | 5,144 | -5,144 | — |
| Svoronos Dawn | Exercise of Derivative Securities | 1.9.2026 | 5,144 | +5,144 | $8.15 |
| KENNEY CHRISTOPHER JOHN | Open Market Sale | 28.8.2026 | 6,368 | -6,368 | $60.17 |
| KENNEY CHRISTOPHER JOHN | Open Market Sale | 28.8.2026 | 700 | -700 | $60.98 |
| KENNEY CHRISTOPHER JOHN | Open Market Sale | 28.8.2026 | 2 | -700 | $60.98 |
| KENNEY CHRISTOPHER JOHN | Open Market Sale | 28.8.2026 | 702 | -6,368 | $60.17 |
| GANNON STEVEN | Open Market Sale | 11.8.2026 | 10,000 | -10,000 | $64.06 |
| GANNON STEVEN | Open Market Sale | 11.8.2026 | 1,870 | -10,000 | $64.06 |
| Cannon Gillian | Open Market Sale | 5.6.2026 | 1,190 | -1,190 | $53.14 |
| PATOU GARY | Open Market Sale | 5.6.2026 | 1,322 | -1,322 | $53.14 |
| PATOU GARY | Open Market Sale | 5.6.2026 | 24,896 | -1,322 | $53.14 |
| Cannon Gillian | Open Market Sale | 5.6.2026 | 1,455 | -1,190 | $53.14 |
| Svoronos Dawn | Grant/Award from Employer | 3.6.2026 | 1,593 | +1,593 | — |
| Svoronos Dawn | Grant/Award from Employer | 3.6.2026 | 10,507 | +10,507 | — |
| GANNON STEVEN | Grant/Award from Employer | 3.6.2026 | 1,593 | +1,593 | — |
| Gover Justin D. | Grant/Award from Employer | 3.6.2026 | 1,593 | +1,593 | — |
| GANNON STEVEN | Grant/Award from Employer | 3.6.2026 | 10,507 | +10,507 | — |
| PATOU GARY | Grant/Award from Employer | 3.6.2026 | 10,507 | +10,507 | — |
| Cannon Gillian | Grant/Award from Employer | 3.6.2026 | 10,507 | +10,507 | — |
| GAROFALO ELIZABETH A. | Grant/Award from Employer | 3.6.2026 | 1,593 | +1,593 | — |
| GAROFALO ELIZABETH A. | Grant/Award from Employer | 3.6.2026 | 10,507 | +10,507 | — |
| Gover Justin D. | Grant/Award from Employer | 3.6.2026 | 10,507 | +10,507 | — |
| Machado Patrick | Grant/Award from Employer | 3.6.2026 | 10,507 | +10,507 | — |
| Machado Patrick | Grant/Award from Employer | 3.6.2026 | 1,593 | +1,593 | — |
| PATOU GARY | Grant/Award from Employer | 3.6.2026 | 1,593 | +1,593 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
6,344,135 shares short as of 2026-08-31 · vs. 5,384,476 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
56.2% of trading volume this week was short selling, vs. 61.5% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology